Kidney Disease
161
129-144 of 145
- CDMC 2018: Shifting gears in the management of diabetes and CVDTranslating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
Dr. Adie Viljoen, MD
- CDMC 2018: Shifting gears in the management of diabetes and CVDBenefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM
Prof. Eduard Montanya, MD
Steve Wiviott, MD
- Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibitionRemaining questions on SGLT2 inhibition & CKD: A review of new outcome trials
Prof. Colin Baigent
- Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibitionSGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME
Prof. Christoph Wanner
- Epigenetics in CKD & CVD: A potential breakthrough therapy?Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD
- Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibitionUnderstanding CKD and SGLT2-inhibition: What are the key mechanisms?
Prof. Per-Henrik Groop
- Epigenetics in CKD & CVD: A potential breakthrough therapy?Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics
Prof. Erik Stroes, MD
- Epigenetics in CKD & CVD: A potential breakthrough therapy?A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives
Kamyar Kalantar-Zadeh, MD
- InflammationAnti-inflammatory treatment also gives MACE reduction in high-risk patients with kidney disease
Dr. Paul Ridker
- Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?
Kamyar Kalantar-Zade, MD
- Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?
Luis M Ruilope, MD
Prof. George L Bakris, MD
